Search

everythinglearnresearchcommunity

for

Search:↓

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

Hair loss treatments, specifically Pyrilutamide and Minoxidil/Finasteride/RU58841. Participants discussed their experiences with them and the results they have seen so far.

The user has been using Finasteride for hair loss and is considering adding alphatradiol, stemoxydine, or 2% minoxidil to their regimen. They are concerned that stemoxydine, which shortens the resting phase of hair, might accelerate hair loss in those not using Finasteride by depleting hair cycles without strengthening miniaturized hairs.

The conversation is about using tretinoin to enhance the effects of minoxidil for hair loss, with suggestions to switch from finasteride to dutasteride or use RU58841 for better results. Concerns about tretinoin causing dry scalp and its potential impact on hair loss progression are also discussed.

Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.

A 33-year-old man used Minoxidil 5% and Tretinoin 0.05% for a year to address hair thinning and receding hairline, resulting in new "baby hairs" filling in thin spots. He applies Tretinoin first, lets it dry, then applies Minoxidil, and notes that consistent use is necessary to maintain results.

The user had high DHT levels after 8 months on dutasteride, questioning the drug's authenticity. They got dutasteride from a legitimate source and will update on progress.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.

KY19382, a promising compound for hair loss, is not widely discussed or used. One user is currently testing it and plans to share results in a few weeks.

The conversation is about a user's hair regrowth progress using topical minoxidil, with plans to start finasteride. The user also takes Vitamin D and washes their hair 2-3 times a week.

RU-58642 is a powerful anti-androgen that was not developed further, possibly due to safety concerns or financial reasons. RU58841 is a topical alternative, but it is less effective than finasteride and dutasteride, and its long-term effects are not well-studied.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

The user has maintained their hairline with finasteride for 5 years and saw no results from minoxidil. They are inquiring if tretinoin alone can cause hair regrowth.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

The user has been using Minoxidil for 4 years and recently added a derma pen and Trinov to their regimen, but results are inconclusive after 3 months. Some users suggest Trinov is ineffective and recommend alternatives like Clascoterone (Breezula) for better results.

An 18-year-old is using a high-dose hair loss treatment regimen including finasteride, minoxidil, dutasteride, and plans to add RU58841 and bimatoprost, despite warnings from others about the risks. The user is determined to reverse hair loss but acknowledges the potential dangers and does not recommend others follow their approach.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

The conversation discusses hair shedding after starting a treatment regimen including topical dutasteride, RU58841, minoxidil, and keto shampoo. Shedding is considered normal, and users suggest adjustments like increasing dutasteride dosage or using oral medications for better results.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

A 29-year-old male shares his hair loss treatment progress using dutasteride, minoxidil, dermastamping, and ketoconazole shampoo, while discontinuing RU58841 due to side effects. He is hopeful for hair recovery to consider a hair transplant and discusses potential side effects and experiences with other users.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

The conversation discusses using tretinoin for hair loss and whether applying SPF on the scalp is necessary if hair covers the treated areas. The user is considering this treatment despite having no completely bald patches.

Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.

The conversation discusses experiences with PTD-DBM for hair loss treatment. It also mentions using Minoxidil, finasteride, and RU58841.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

A user received a prescription for a topical solution with Minoxidil 7%, Finasteride 2%, and Tretinoin 0.01%, to be used twice daily for three months. They are concerned about the safety of these dosages compared to commonly recommended lower dosages.